

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.e-jds.com



Original Article

Association of dietary zinc consumption with periodontitis in diabetes mellitus patients: A cross-sectional study of national health and nutrition examination surveys database (2009–2014)



Mingdi Xiang, Zhiwen Pan, Siqian Hong, Guifen Cao, Bin Feng*

Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Hangzhou, Zhejiang, PR China

Received 10 July 2023; Final revision received 18 July 2023 Available online 4 August 2023

KEYWORDS Dietary Zn intake; Periodontitis; Cross sectional study; Diabetes mellitus	Abstract Background/purpose: Periodontitis is an independent risk factor for diabetes mel- litus (DM), and DM patients had an increased risk in susceptibility to periodontitis. And serum zinc (Zn) levels were low in patients with periodontitis combined with DM. Herein, this study aimed to explore the association between dietary Zn intake and the risk of periodontitis in DM patients, in order to provide some scientific references for the prevention and treatment for periodontitis clinically. <i>Materials and methods:</i> Demographic and clinical data of DM patients were extracted from the National Health and Nutrition Examination Surveys (NHANES) database in 2009−2014 in this cross-sectional study. Weighted univariate logistic regression and backward regression analyses were used for covariates screening. Weighted univariate and multivariate logistic regression analyses were used to explore the association between Zn and periodontitis with odds ratios (ORs) and 95% confidence intervals (CIs). Subgroup analyses of age and gender were also per- formed. <i>Results:</i> Of the eligible participants, 1281 had moderate or severe periodontitis. After adjust- ing for the covariates, we found that comparing to DM patients who had not reach the recom- mended Zn intake level, those who reached had low odds for periodontitis [OR = 0.76, 95% CI: (0.58−0.99)]. In patients who aged ≥65 years old [OR = 0.59, 95% CI: (0.36−0.97)] and were female [OR = 0.71, 95% CI: (0.51−0.99)], reaching the recommended level of Zn intake was related to low odds of periodontitis.
---	---

* Corresponding author. Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, No. 166 Qiutao North Road, Xihu District, Hangzhou 310000, Zhejiang, PR China.

E-mail address: 7515024@zju.edu.cn (B. Feng).

https://doi.org/10.1016/j.jds.2023.07.025

1991-7902/© 2023 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Conclusion: Sufficient dietary Zn intake antagonized the risk of periodontitis, which may provide some references for diet management in DM patients to reduce the risk of periodontitis. © 2023 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Periodontitis is the sixth most prevalent chronic disease characterized by the inflammation of the deep tissue leading to periodontal ligament disruption, and alveolar bone loss, often resulting in tooth loss.¹ Periodontitis increases the risk of masticatory dysfunction and negatively affects the quality of life in patients.² Periodontitis is an independent risk factor for diabetes mellitus (DM), and studies have reported that DM patients had an approximately threefold increase in susceptibility to periodontitis.^{3,4} Elevated levels of oxidative stress and inflammation due to hyperglycemia and consequent damage to periodontal tissue may be a potential mechanism for the increased risk of periodontitis in DM patients.⁴ Therefore, it is necessary to explore the influencing factors for the development of periodontitis in DM patients, in order to find potential avenues of prevention and control of periodontitis.

Antioxidant or anti-inflammatory dietary minerals may have a potential impact on the development of periodontitis.⁵ A limited number of studies have found that inadequate dietary zinc (Zn) intake may be associated with an increased risk of periodontitis.⁶ Zn deficiency may alter oral mucosal thickness and keratinization to increase the risk of infection, as well as affect immune cell function and antioxidant enzyme levels to influence periodontitis.⁷ In addition, Zn can improve oxidative stress and chronic inflammatory state in DM.⁸ Also, Thomas et al.⁹ found that serum Zn levels were lower in patients with periodontitis combined with DM compared with the healthy population or patients with periodontitis only. However, studies analyzing the relationship between nutritional status of Zn and the risk of periodontitis in DM patients have been scarce.

Herein, this study aimed to explore the association between dietary Zn intake and the risk of periodontitis in DM patients, in order to provide some scientific references for the prevention and treatment for periodontitis clinically.

Materials and methods

Study design and participants

Demographic and clinical data of DM patients were extracted from the National Health and Nutrition Examination Surveys (NHANES) database in 2009–2014 in this cross-sectional study. NHANES aims to assess the nutritional and health status of the noninstitutionalized population in the U.S., which is conducted by the Centers for Disease Control and Prevention (CDC) and the National Center for Health Statistics (NCHS). NHANES uses a complex, multistage stratified probability sampling method based on selected counties, blocks, households, and persons within households. Interviews in participants' homes conducted by the NCHS trained professionals, and extensive physical examinations including blood and urine collection were conducted at mobile exam centers (MECs). Details of study implementation are available for online access: https://www.cdc.gov/ nchs/nhanes/index.htm.

A total of 2032 DM patients received the oral health exam were initially included. Those who missing information of dietary Zn intake were excluded. Finally, 1914 of them were eligible. NHANES was approved by the institutional review board (IRB) of NCHS. The data were deidentified and all the participants provided informed consent. No ethical approval of our agency's IRB was required since this survey was publicly available.

Diagnosis of diabetes mellitus

DM was defined according to a self-reported diagnosis, the use of oral hypoglycemic agents or insulin, glycosylated hemoglobin (HbAlc) \geq 6.5%, a plasma glucose level \geq 200 mg/dL at 2-h after the oral glucose tolerance test (OGTT), or a fasting glucose level \geq 126 mg/dL.¹⁰

Assessment of dietary zinc consumption

Dietary intake of Zn and its supplements from NHANES was based on the two 24-h dietary recall surveys. The first 24-h recall interview was conducted in person in the MEC by trained interviewers, and the second interview was performed by telephone or mail three to ten days later. We used the records of first 24-h recall in this study to minimize the recall bias.

Zn intake levels were divided into two levels according to the dietary reference intakes (DRIs), including reach the recommended level and not reach the recommended level. The recommended dietary Zn intake for males is \geq 11 mg and that for female is \geq 8 mg, the details can be found on the website: https://www.ncbi.nlm.nih.gov/ books/NBK545442/table/appJ_tab3/?report=objectonly.

Examination of periodontitis

Participants had a full-mouth periodontal examination, and all the dental examiners were trained and calibrated by the NHANES survey's reference examiner.¹¹ The measurement of gingival recession and pocket depth for 6 sites/tooth (including wisdom teeth) used a color-coded periodontal probe with graduated in 2-mm increments (HU-Friedy, Chicago, IL, USA). All 4 quadrants were examined, and all measurements were rounded to the lowest whole millimeter. Then the clinical attachment loss (CAL), namely the difference between pocket depth and gingival recession, at each site was calculated by an algorithm in the data entry program.¹² The proportion of sites with CAL \geq 3 mm (i.e., CAL extent) was used to estimate periodontitis, which has been recommended for epidemiological studies as an extent measure.¹³ In addition, mean CAL and mean pocket probing depth (PPD) per mouth in millimeters were calculated for description of measuring other aspects of periodontitis.

Non-periodontitis is defined as no evidence of mild, moderate, or severe periodontitis. Mild periodontitis means ≥ 2 interproximal sites with CAL ≥ 3 mm, and ≥ 2 interproximal sites with PPD ≥ 4 mm (not on same tooth) or one site with PPD ≥ 5 mm. Moderate periodontitis represents there are ≥ 2 interproximal sites with CAL ≥ 4 mm (not on same tooth), and ≥ 2 interproximal sites with CAL ≥ 4 mm (not on same tooth). And severe periodontitis means ≥ 2 interproximal sites with CAL ≥ 6 mm (not on same tooth), and ≥ 1 interproximal sites with PPD ≥ 5 mm. In this study we divided the varying degrees of periodontitis into two levels, ⁶ that are non-periodontitis/mild periodontitis, and moderate/severe periodontitis.

Variables collection

We collected potential confounding factors including age, gender, race, education level, poverty income ratio (PIR), smoking, drinking, physical activity, body mass index (BMI), diabetic retinopathy, white blood cell (WBC), antibiotics drug, anti-diabetic drug, hypertension, cardiovascular disease (CVD), hepatitis, dyslipidemia, autoimmune disease, decayed teeth, dental implant, tooth loss, dental floss use, total energy intake, protein, fiber, calcium (Ca), iron, copper (Cu), and chronic kidney disease (CKD).

Hypertension was defined by the laboratory inspection, self-reported hypertension or currently use of hypotensive drugs, or a measured systolic blood pressure (SBP) >140 mm Hg or diastolic blood pressure (DBP) \geq 90 mm Hg.¹⁴ Patients with TC \geq 200 mg/dL (5.2 mmol/L) or triglycerides (TG) >150 mg/dL (1.7 mmol/L) or low-density lipoprotein cholesterol (LDL-C) >130 mg/dL (3.4 mmol/L) or high-density lipoprotein cholesterol (HDL-C) <40 mg/dL (1.0 mmol/L) or selfreported hypercholesteremia or receiving lipid-lowering therapy were identified as dyslipidemia.¹⁵ CVD was determined by multiple choice question (MCQ) in NHANES: "Have you ever been told you had (congestive) heart failure, coronary heart disease, angina/angina pectoris, heart attack, stroke." Participants smoked at least 100 cigarettes in their life according to smoking motivation questionnaire (SMQ)-D are considered as a smoker, otherwise are considered as a non-smoker. If they have guit smoking for more than one year (current non-smoker) defined as a former smoker. The pattern of alcohol consumption was captured by questionnaires, and the participants were divided into non-drinker, current non-drinker (have quit drinking in the past year), and drinker.¹⁶ Physical activity was converted to metabolic equivalent (MET), which was calculated according to the physical activity questionnaire (PAQ) in NHANES. Energy expenditure (MET \cdot min) = recommended MET \times exercise time of corresponding activity (min). Dietary intakes including total energy, protein, fiber, Ca, iron, and Cu were calculated by "Total nutrient intakes" and "Total dietary supplements" from 24-h dietary recalls of NHANES. CKD was defined as estimate glomerular filtration rate (eGFR) <60 ml/min per 1.73 m² or urine albumin-to-creatinine ratio (UACR) \geq 30 mg/g.¹⁷ Autoimmune disease was diagnosed if participants have one of the following diseases: rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis, and thyroiditis through the questionnaires.

Statistical analysis

Measurement data were described using mean \pm standard error (mean \pm SE) and independent-samples t test for group comparison. Enumeration data were expressed as number with constituent ratio [N (%)] and chi-square test for the comparison. Ranked data examination was used the rank sum test. We used a set of weights "WTDRD1" because we used the day 1 dietary recall data for analyses. Day 1 weights were constructed by taking the 2-year MEC sample weights (WTMEC2YR) and further adjusting for (a) the additional non-response and (b) the differential allocation by day of the week for the dietary intake data collection (https://wwwn.cdc.gov/Nchs/Nhanes/2007-2008/DR1IFF_D.htm#WTDRD1).

Weighted univariate logistic regression analysis as well as backward regression were used to screen the covariates that related to periodontitis. Weighted univariate and multivariate logistic regression analyses were used to explore the association between dietary Zn intake and the risk of periodontitis. Model 1 was the crude model. Model 2 adjusted for age, gender, race, PIR, smoking, and dental implants.

The evaluation index was odds ratios (ORs) with 95% confidence intervals (CIs). Two-sided *P*-values < 0.05 was considered significant. Statistical analysis was performed using SAS 9.4 (SAS Institute, Cary, NC, USA). Missing variables were PIR, WBC, dental floss use, BMI and smoking. We used multiple imputation for the interpolation of missing variables, and the sensitivity analysis of patients' characteristics before and after the multiple imputation were showed in Table S1.

Results

Characteristics of study population

A total of 2032 DM patients receiving oral health exam were initially included. Those who missing the information of Zn intake (n = 118) were excluded. Finally, 1914 of them were eligible (Fig. 1).

Of all the eligible DM patients, 633 had nonperiodontitis/mild periodontitis, and 1281 had moderate/ severe periodontitis. The characteristics of participants were showed in Table 1. The average age of the patients was 58.34 years old. Male share 52.68% while female share 47.32%. There were respectively 421 (70.17%) and 745 (61.47%) DM patients who not achieve the recommended dietary Zn intake between non-periodontitis/mild periodontitis group and moderate/severe periodontitis group.



Figure 1 Flowchart of participants screening in the current study.

Additionally, significant differences were also found between non-periodontitis/mild periodontitis group and moderate/severe periodontitis group in race, education level, PIR, smoking, BMI, hypertension, CVD, hepatitis, decayed teeth, dental implant, tooth loss, and dental floss use (all *P*-values < 0.05).

Association between dietary Zn intake and periodontitis

We first screened for the covariates linked to periodontitis (Table 2), and found that age, gender, race, education level, PIR, smoking, BMI, hypertension, CVD, hepatitis, decayed teeth, dental implant, tooth loss, and dental floss use were significantly associated with periodontitis (all *P*-values < 0.05). Then, we used the backward regression and selected the final covariates for further analysis including age, gender, race, PIR, smoking, and dental implants.

After adjusting for the covariates, the results showed that comparing to DM patients who had not reach the recommended Zn intake level, those reached the recommended level had low odds for periodontitis [OR = 0.76, 95% CI: (0.58-0.99)] (Table 3).

Role of Zn intake in periodontitis in subgroups of age and gender

The relationship of dietary Zn intake and periodontitis was further explored in DM patients with different age and gender (Table 4). Patients who aged <65 years old seemed to have low odds of periodontitis when their Zn intake achieved the recommended levels [OR = 0.70, 95% CI: (0.50–0.99)], and however, after adjusting for covariates, this association disappeared (*P*-value = 0.268). In those who aged \geq 65 years old [OR = 0.59, 95% CI: (0.36–0.97)] and were female [OR = 0.71, 95% CI: (0.51–0.99)], reaching the recommended level of Zn intake was related to the decreased risk of periodontitis.

Discussion

In this cross-sectional study, we explored the relationship between dietary Zn intake and periodontitis in DM patients. The results indicated that dietary Zn consumption reached the recommended level was linked to low odds of periodontitis comparing to those not reach. Besides, in DM patients who aged \geq 65 years old or were female, high intake levels of Zn seemed to be associated with a decreased risk of periodontitis.

To our knowledge, no study have explored the role of dietary Zn intake in periodontitis in DM patients so far. Thomas et al.⁹ compared the Zn status in the serum of DM patients and healthy individuals with periodontitis, and found a decreased level of Zn in diabetic patients with periodontitis. In reality, DM is an independent risk factor for periodontitis,³ and nutrition status is also a key modifiable factor for periodontitis.¹⁸ Zn is present in oral environment, daily diet, oral health products, and dental restorative materials.¹⁹ Liu et al.¹⁹ summarized the regulatory effect of Zn during periodontitis process, indicating that Zn supplementation may enhance immune defense or accelerate local cells proliferation and differentiation, and further promote periodontal regeneration. Aziz et al.²⁰ found that a disrupted Zn homeostasis was expected to exert a negative effect on periodontal health and related to periodontitis' development and progression. A study of NHANES database explored the relationship of serum Zn and periodontitis in non-DM smoking and non-smoking adults, which showed that serum Zn levels were linked to the risk of periodontitis in non-DM smokers but not non-smokers.²¹ In the current study, we additionally discovered high dietary intake level of Zn (i.e., reaching WHO recommended level) was associated with low odds of periodontitis.

Zn is a high abundant trace mineral necessary for human body, which primary source includes spinach, protein-rich foods, nuts, and fortified cereals.^{5,22,23} Zn has antioxidative properties, neutralizes bacterial toxins, and is also a cofactor in enzyme-controlled processes.^{22,24} The pathogenesis of periodontitis is complex due to it involves diverse microbial floras and its products combining with the chronic inflammatory process.9 Deficiency of Zn may increase the susceptibility to infection through increasing the permeability of gingival epithelium for bacteria, as well as impair neutrophils and macrophages functions and stimulate them to interleukin-1 (IL-1) production.²⁵ The mechanisms of DM increasing phlogistic process for periodontal tissues are different. In patients with DM, advanced glycation endproducts (AGEs) and their receptors (RAGEs) are interacted and deposited in the periodontal tissues activating the local inflammation. This interaction increased the release of pro-inflammatory cytokines by monocytes/macrophages and endothelial cells, such as IL-18, IL-6, and tumor necrosis factor (TNF)- α .^{26,27} This exacerbated inflammation may further increase the periodontal inflammation and attachment, and bone loss.^{28,29} We hypothesized that in DM patients, adequate dietary Zn intake may neutralize bacterial toxins and alleviate local inflammation, thereby reducing the risk of periodontitis.

Table 1	Characteristics of	^f the DM patients in	the current study.
---------	--------------------	---------------------------------	--------------------

Age, years, Mean (S.E) 58.34 (0.38) 55.04 (0.56) 60.48 (0.46) <0.001	Variables	Total (n = 1914)	Non-periodontitis/ mild periodontitis (n = 633)	Moderate/severe periodontitis (n = 1281)	Р
	Age, years, Mean (S.E)	58.34 (0.38)	55.04 (0.56)	60.48 (0.46)	<0.001
Male 996 (52.68) 253 (43.44) 743 (58.56) Female 918 (47.32) 380 (56.56) 538 (41.36) Race, n (%) <0.001	Gender, n (%)				<0.001
Female 918 (47.32) 380 (55.56) 538 (41.36) Maxican American 339 (10.54) 73 (6.79) 266 (12.66) 480 (6.92) Mon-Hispanic 219 (6.90) 71 (6.66) 148 (6.92) 0.001 Non-Hispanic Black 566 (15.46) 158 (13.58) 346 (16.68) 0.001 Cherr Race 196 (9.21) 67 (7.82) 129 (10.12) 0.001 Education level, n (%) <0.001	Male	996 (52.68)	253 (43.44)	743 (58.65)	
Race, n (%)	Female	918 (47.32)	380 (56.56)	538 (41.36)	
Mexican American 339 (10.54) 73 (6.79) 266 (12.96) Oher Hispanic White 654 (57.89) 244 (64.95) 300 (33.33) Non-Hispanic White 656 (15.46) 158 (13.58) 348 (16.68) Other Rize 196 (9.21) 67 (7.82) 129 (10.12) Education level, n (%)	Race, n (%)				<0.001
Other Hispanic 219 (6.90) 71 (6.86) 148 (6.92) Non-Hispanic White 654 (57.89) 264 (64.95) 390 (53.33)	Mexican American	339 (10.54)	73 (6.79)	266 (12.96)	
Non-Hispanic White 654 (57.89) 264 (64.95) 390 (33.3) Non-Hispanic Black 566 (15.46) 158 (13.58) 348 (16.68) Other Race 196 (9.21) 67 (7.82) 129 (10.12) Education level, n (%)	Other Hispanic	219 (6.90)	71 (6.86)	148 (6.92)	
Non-Hispanic Black 56 (15.4c) 158 (13.58) 348 (16.6c) Other Race 196 (9.21) 67 (7.82) 129 (10.12) Education level, n (%) - <0.001	Non-Hispanic White	654 (57.89)	264 (64.95)	390 (53.33)	
Other Race 196 (9.21) 67 (7.82) 129 (10.12) Education level, n (%) <	Non-Hispanic Black	506 (15.46)	158 (13.58)	348 (16.68)	
Education level, n (%) Less than 9 th grade 297 (13.10) 77 (10.67) 220 (14.67) 120 (23.64) 298 (23.69) High school graduate 424 (23.67) 126 (23.64) 298 (23.69) 30.71) College graduate 359 (21.85) 165 (27.85) 194 (17.96) 100.071 Unknown 4 (0.07) 1 (0.03) 3 (0.10) 0.001 PIR, Mean (S.E) 2.72 (0.06) 3.09 (0.08) 2.49 (0.08) <0.001	Other Race	196 (9.21)	67 (7.82)	129 (10.12)	
Less than 9th grade 294 (9.51) 47 (4.30) 247 (12.88) 9-11th grade 297 (13.10) 77 (10.67) 220 (14.67) High school graduate 424 (23.67) 126 (23.64) 298 (23.69) Ad degree 336 (31.81) 217 (33.52) 319 (30.71) College graduate 359 (21.85) 165 (27.85) 194 (17.96) Unknown 4 (0.07) 1 (0.03) 3 (0.10) PIR, Mean (5.E) 2.72 (0.06) 3.09 (0.08) 2.49 (0.08) <0.001 Smoking, n (%) Never smoked 1029 (51.96) 394 (59.99) 635 (46.76) Quitting 065 (33.93) 182 (31.54) 423 (35.48) Current smoker 280 (14.11) 57 (8.47) 223 (17.76) No No No No No No No No No No	Education level, n (%)				<0.001
9-11th grade 297 (13.10) 77 (10.67) 220 (14.67) High school graduate 242 (23.67) 126 (23.64) 298 (23.69) AA degree 356 (31.81) 217 (33.52) 319 (30.71) College graduate 359 (21.85) 165 (27.85) 194 (17.96) Unknown 4 (0.07) 1 (0.03) 3 (0.10) PIR, Mean (S.E) 2.72 (0.06) 3.09 (0.08) 2.49 (0.08) <0.001	Less than 9th grade	294 (9.51)	47 (4.30)	247 (12.88)	
High school graduate424 (23.67)126 (23.64)298 (23.69)AA degree536 (31.81)217 (33.52)319 (30.71)College graduate359 (21.85)165 (27.85)194 (17.96)Unknown4 (0.07)1 (0.03)3 (0.10)PlR, Mean (S.E)2.72 (0.69)3.09 (0.08)2.49 (0.08)Smoking, n (%)Never smoked1029 (51.96)394 (59.99)635 (46.76)Quitting605 (33.93)182 (31.54)423 (35.48)Current smoker208 (14.11)57 (8.47)423 (15.68)Drinking, n (%)536 (47 (28.29)52.502 (48.48)533 (40.52)Yes512 (30.58)181 (34.44)331 (28.08)Physical activity, MET-min, Mean (S.E)53.64 (28.29)52.502 (48.48)533 (40.52)0.779Ma, kg/m², Mean (S.E)243 (11.76)69 (8.71)174 (13.74)2529.9549 (25.40)159 (24.10)390 (26.24) ≥ 30 1122 (62.84)405 (67.20)777 (60.02)101012Diabetic retinopathy, n (%)0.598No1048 (55.55)340 (55.60)708 (57.17)Yes209 (9.12)59 (8.28)150 (9.66)Unknown657 (34.33)234 (36.12)423 (33.16)No1048 (55.55)340 (55.60)708 (57.17)Yes23 (1.46)111 (1.70)12 (1.11)No1048 (56.55)34	9—11th grade	297 (13.10)	77 (10.67)	220 (14.67)	
AA degree 536 (31.81) 217 (33.52) 319 (30.71) College graduate 359 (21.85) 165 (27.85) 194 (17.96) Unknown 4 (0.07) 1 (0.03) 3 (0.10) PIR, Mean (S.E) 2.72 (0.06) 3.09 (0.08) 2.49 (0.08) <0.001	High school graduate	424 (23.67)	126 (23.64)	298 (23.69)	
College graduate 359 (21.85) 165 (27.85) 194 (17.96) Unknown 4 (0.07) 1 (0.03) 3 (0.10) $-$ PIR, Mean (S.E) 2.72 (0.06) 3.09 (0.08) 2.49 (0.08) <0.001	AA degree	536 (31.81)	217 (33.52)	319 (30.71)	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	College graduate	359 (21.85)	165 (27.85)	194 (17.96)	
PIR, Mean (S.E) 2.72 (0.06) 3.09 (0.08) 2.49 (0.08) <0.001	Unknown	4 (0.07)	1 (0.03)	3 (0.10)	
Smoking, n (%) < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <	PIR, Mean (S.E)	2.72 (0.06)	3.09 (0.08)	2.49 (0.08)	<0.001
Never smoked1029 (51.96)394 (59.99)635 (46.76)Quitting605 (33.93)182 (31.54)423 (35.48)Current smoker280 (14.11)57 (8.47)223 (17.76)Drinking, n (%)	Smoking, n (%)				<0.001
Quitting Current smoker605 (33.93) 280 (14.11)182 (31.54) 77 (8.47)423 (35.48) 223 (17.76)Drinkling, n (%)	Never smoked	1029 (51.96)	394 (59.99)	635 (46.76)	
Current smoker 280 (14.11) 57 (8.47) 223 (17.76) Drinking, n (%) 0.056 No 1402 (69.42) 452 (65.56) 950 (71.92) Yes 512 (30.58) 181 (34.44) 331 (28.08) 0.779 Physical activity, MET-min, Mean (S.E) 536.47 (29.29) 525.02 (48.48) 543.87 (40.52) 0.779 SMM, kg/m², Mean (S.E) 243 (11.76) 69 (8.71) 174 (13.74) 0.031 25-29.9 243 (12.62.84) 405 (67.20) 717 (60.02) 0.598 No 1048 (56.56) 340 (55.60) 708 (57.17) 0.598 No 1048 (56.56) 340 (55.60) 708 (57.17) 0.640 Unknown 657 (34.33) 234 (36.12) 423 (33.16) 0.556 Anti-diabetic drug, n (%)	Quitting	605 (33.93)	182 (31.54)	423 (35.48)	
Drinking, n (%)0.056No1402 (69.42)452 (65.56)950 (71.92)Yes512 (30.58)181 (34.44)331 (28.08)Physical activity, MET-min, Mean (S.E)536.47 (29.29)525.02 (48.48)543.87 (40.52)0.779BMI, kg/m², Mean (S.E)243 (11.76)69 (8.71)174 (13.74)≥5-29.9549 (25.40)159 (24.10)390 (26.24)≥301024 (26.28)405 (67.20)717 (60.02)Diabetic retinopathy, n (%)	Current smoker	280 (14.11)	57 (8.47)	223 (17.76)	
No1402 (69.42)452 (65.56)950 (71.92)Yes512 (30.58)181 (34.44)331 (28.08)Physical activity, MET-min, Mean (S.E)536.47 (29.29)525.02 (48.48)543.87 (40.52)0.779BMI, kg/m², Mean (S.E)243 (11.76)69 (8.71)174 (13.74)0.031 <225 243 (11.76)69 (8.71)174 (10.02)0.779Diabetic retinopathy, n (%)1122 (62.84)405 (67.20)717 (60.02)0.598No1048 (56.56)340 (55.60)708 (57.17)0.598Ves209 (9.12)59 (8.28)150 (9.66)0.556Unknown657 (34.33)234 (36.12)423 (33.16)WBC, 1000 cells/µL, Mean (S.E)7.63 (0.08)7.57 (0.16)7.67 (0.08)0.556No763 (39.80)259 (40.71)504 (39.21)0.640No763 (39.80)259 (40.71)504 (39.21)0.635No115 (60.20)374 (59.29)777 (60.79)6.55Anti-diabetic drug, n (%) (39.16) 11 (1.70)12 (1.31)No129 (17.16)132 (21.99)197 (14.03)0.640Yes1385 (82.84)501 (78.01)1084 (85.97)0.004No329 (17.24)91 (13.43)248 (19.70)0.004No1558 (82.07)540 (86.28)1018 (79.34)148Yes339 (17.24)91 (13.43)248 (19.70)0.04No1558 (82.07)540 (86.28)1018 (79.34)148Yes339 (17.24)91 (13.43)248 (19.70) </td <td>Drinking, n (%)</td> <td></td> <td></td> <td></td> <td>0.056</td>	Drinking, n (%)				0.056
Yes512 (30.58)181 (34.44)331 (28.08)Physical activity, MET-min, Mean (S.E)536.47 (29.29)525.02 (48.48)543.87 (40.52)0.779BMI, kg/m², Mean (S.E)0.0310.252.02 (48.48)543.87 (40.52)0.719 <25 243 (11.76)69 (8.71)174 (13.74)0.031 <25 243 (11.76)69 (8.71)174 (13.74)0.031 <25 243 (11.76)69 (8.71)174 (13.74)0.031 >300 1122 (62.84)405 (67.20)717 (60.02)0.798Diabetic retinopathy, n (%)0.788 (57.17)0.5980.966)0.598No1048 (56.56)340 (55.60)708 (57.17)0.598Ves209 (9.12)59 (8.28)150 (9.66)0.640Unknown657 (34.33)234 (36.12)423 (33.16)0.556MCC, 1000 cells/µL, Mean (S.E)7.63 (0.08)7.57 (0.16)7.67 (0.08)0.556Anti-diabetic drug, n (%)622 (98.30)1269 (98.69)0.635No763 (39.80)259 (40.71)504 (39.21)400.635Yes1151 (60.20)374 (59.29)777 (60.79).Anti-diabetic drug, n (%)229 (17.16)132 (21.99)197 (14.03)Yes23 (1.46)11 (1.70)12 (1.31).No1585 (82.07)540 (86.28)1018 (79.34).Yes339 (17.24)91 (13.43)248 (19.70).Unknown17 (0.70)2 (0.30)15 (0.95).No1614 (85.42) <t< td=""><td>No</td><td>1402 (69.42)</td><td>452 (65.56)</td><td>950 (71.92)</td><td></td></t<>	No	1402 (69.42)	452 (65.56)	950 (71.92)	
Physical activity, MET·min, Mean (S.E) 53.6.47 (29.29) 525.02 (48.48) 543.87 (40.52) 0.779 BMI, Kg/m ² , Mean (S.E) 0.031 <25	Yes	512 (30.58)	181 (34.44)	331 (28.08)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Physical activity, MET · min, Mean (S.E)	536.47 (29.29)	525.02 (48.48)	543.87 (40.52)	0.779
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	BMI, kg/m ² , Mean (S.E)				0.031
$25-29.9$ 549 (25.40) 159 (24.10) 390 (26.24) ≥ 30 1122 (62.84)405 (67.20) 717 (60.02)Diabetic retinopathy, n (%)	<25	243 (11.76)	69 (8.71)	174 (13.74)	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	25–29.9	549 (25.40)	159 (24.10)	390 (26.24)	
Diabetic retinopathy, n (%) 0.598 No 1048 (56.56) 340 (55.60) 708 (57.17) Yes 209 (9.12) 59 (8.28) 150 (9.66) Unknown 657 (34.33) 234 (36.12) 423 (33.16) WBC, 1000 cells/µL, Mean (S.E) 7.63 (0.08) 7.57 (0.16) 7.67 (0.08) 0.556 Antibiotics drug, n (%)	≥30	1122 (62.84)	405 (67.20)	717 (60.02)	
No1048 (56.56)340 (55.60)708 (57.17)Yes209 (9.12)59 (8.28)150 (9.66)Unknown657 (34.33)234 (36.12)423 (33.16)WBC, 1000 cells/µL, Mean (S.E)7.63 (0.08)7.57 (0.16)7.67 (0.08)0.556Antibiotics drug, n (%)	Diabetic retinopathy, n (%)				0.598
Yes209 (9.12)59 (8.28)150 (9.66)Unknown657 (34.33)234 (36.12)423 (33.16)WBC, 1000 cells/µL, Mean (S.E)7.63 (0.08)7.57 (0.16)7.67 (0.08)0.556Antibiotics drug, n (%)763 (39.80)259 (40.71)504 (39.21)0.640No763 (39.80)259 (40.71)504 (39.21)0.640Yes1151 (60.20)374 (59.29)777 (60.79)0.635No1891 (98.54)622 (98.30)1269 (98.69)0.635No1891 (98.54)622 (98.30)1269 (98.69)0.001Yes23 (1.46)11 (1.70)12 (1.31)0.001Hypertension, n (%) $(5.28.44)$ 501 (78.01)1084 (85.97)0.004No329 (17.16)132 (21.99)197 (14.03)0.004Yes1585 (82.07)540 (86.28)1018 (79.34)0.004Yes339 (17.24)91 (13.43)248 (19.70)0.004No157 (0.70)2 (0.30)152 (11.22)0.348No1614 (85.42)544 (87.23)1070 (84.25)0.348No1614 (85.42)544 (87.23)1070 (84.25)0.003No1614 (85.42)544 (87.23)1070 (84.25)0.003	No	1048 (56.56)	340 (55.60)	708 (57.17)	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Yes	209 (9.12)	59 (8.28)	150 (9.66)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Unknown	657 (34.33)	234 (36.12)	423 (33.16)	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	WBC, 1000 cells/µL, Mean (S.E)	7.63 (0.08)	7.57 (0.16)	7.67 (0.08)	0.556
No763 (39.80)259 (40.71)504 (39.21)Yes1151 (60.20)374 (59.29)777 (60.79)Anti-diabetic drug, n (%)0.635No1891 (98.54)622 (98.30)1269 (98.69)Yes23 (1.46)11 (1.70)12 (1.31)Hypertension, n (%) $< 23 (1.46)$ 11 (1.70)12 (1.31)No329 (17.16)132 (21.99)197 (14.03)Yes1558 (82.84)501 (78.01)1084 (85.97)CVD, n (%) $< 339 (17.24)$ 91 (13.43)248 (19.70)No1558 (82.07)540 (86.28)1018 (79.34)Yes339 (17.24)91 (13.43)248 (19.70)Unknown17 (0.70)2 (0.30)15 (0.95)CKD, n (%) < 0.348 0.339 (17.24)91 (13.43)No1614 (85.42)544 (87.23)1070 (84.25)Yes205 (10.23)53 (8.70)152 (11.22)Unknown95 (4.35)36 (4.07)59 (4.53)No1657 (90.12)563 (93.24)1094 (88.11)Yes183 (6.57)42 (3.70)141 (8.43)Unknown74 (3.31)28 (3.06)46 (3.47)	Antibiotics drug, n (%)				0.640
Yes1151 (60.20) 374 (59.29) 777 (60.79)Anti-diabetic drug, n (%)0.635No1891 (98.54)622 (98.30)1269 (98.69)Yes23 (1.46)11 (1.70)12 (1.31)Hypertension, n (%) x x $<$ 0.001No329 (17.16)132 (21.99)197 (14.03)Yes1585 (82.84)501 (78.01)1084 (85.97)CVD, n (%) x 0.004 No1558 (82.07)540 (86.28)1018 (79.34)Yes339 (17.24)91 (13.43)248 (19.70)Unknown17 (0.70)2 (0.30)15 (0.95)CKD, n (%) x 0.348 0.348 No1614 (85.42)544 (87.23)1070 (84.25)Yes205 (10.23)53 (8.70)152 (11.22)Unknown95 (4.35)36 (4.07)59 (4.53)No1657 (90.12)563 (93.24)1094 (88.11)Yes183 (6.57)42 (3.70)141 (8.43)Unknown74 (3.31)28 (3.06)46 (3.47)	No	763 (39.80)	259 (40.71)	504 (39.21)	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Yes	1151 (60.20)	374 (59.29)	777 (60.79)	
No $1891 (98.54)$ $622 (98.30)$ $1269 (98.69)$ Yes $23 (1.46)$ $11 (1.70)$ $12 (1.31)$ Hypertension, n (%) $<<<0.001No329 (17.16)132 (21.99)197 (14.03)Yes1585 (82.84)501 (78.01)1084 (85.97)CVD, n (%)0.004No1558 (82.07)540 (86.28)1018 (79.34)Yes339 (17.24)91 (13.43)248 (19.70)Unknown17 (0.70)2 (0.30)15 (0.95)CKD, n (%)0.348No1614 (85.42)544 (87.23)1070 (84.25)Yes205 (10.23)53 (8.70)152 (11.22)Unknown95 (4.35)36 (4.07)59 (4.53)No1657 (90.12)563 (93.24)1094 (88.11)Yes183 (6.57)42 (3.70)141 (8.43)Unknown74 (3.31)28 (3.06)46 (3.47)$	Anti-diabetic drug, n (%)	. ,	. ,	. ,	0.635
Yes23 (1.46)11 (1.70)12 (1.31)Hypertension, n (%) $< 329 (17.16)$ 132 (21.99)197 (14.03)No329 (17.16)132 (21.99)197 (14.03)Yes1585 (82.84)501 (78.01)1084 (85.97)CVD, n (%) < 0.004 0.004No1558 (82.07)540 (86.28)1018 (79.34)Yes339 (17.24)91 (13.43)248 (19.70)Unknown17 (0.70)2 (0.30)15 (0.95)CKD, n (%) < 0.348 0.348No1614 (85.42)544 (87.23)1070 (84.25)Yes205 (10.23)53 (8.70)152 (11.22)Unknown95 (4.35)36 (4.07)59 (4.53)Hepatitis, n (%) < 0.003 0.003No1657 (90.12)563 (93.24)1094 (88.11)Yes183 (6.57)42 (3.70)141 (8.43)Unknown74 (3.31)28 (3.06)46 (3.47)	No	1891 (98.54)	622 (98.30)	1269 (98.69)	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Yes	23 (1.46)	11 (1.70)	12 (1.31)	
No 329 (17.16) 132 (21.99) 197 (14.03) Yes 1585 (82.84) 501 (78.01) 1084 (85.97) CVD, n (%)	Hypertension, n (%)	. ,	. ,		<0.001
Yes 1585 (82.84) 501 (78.01) 1084 (85.97) CVD, n (%) 0.004 No 1558 (82.07) 540 (86.28) 1018 (79.34) Yes 339 (17.24) 91 (13.43) 248 (19.70) Unknown 17 (0.70) 2 (0.30) 15 (0.95) CKD, n (%) 0.348 No 1614 (85.42) 544 (87.23) 1070 (84.25) Yes 205 (10.23) 53 (8.70) 152 (11.22) Unknown 95 (4.35) 36 (4.07) 59 (4.53) Hepatitis, n (%) 0.003 No 1657 (90.12) 563 (93.24) 1094 (88.11) Yes 183 (6.57) 42 (3.70) 141 (8.43) Unknown 74 (3.31) 28 (3.06) 46 (3.47)	No	329 (17.16)	132 (21.99)	197 (14.03)	
CVD, n (%) 0.004 No 1558 (82.07) 540 (86.28) 1018 (79.34) Yes 339 (17.24) 91 (13.43) 248 (19.70) Unknown 17 (0.70) 2 (0.30) 15 (0.95) CKD, n (%) 0.348 No 1614 (85.42) 544 (87.23) 1070 (84.25) Yes 205 (10.23) 53 (8.70) 152 (11.22) Unknown 95 (4.35) 36 (4.07) 59 (4.53) Hepatitis, n (%) 0.003 No 1657 (90.12) 563 (93.24) 1094 (88.11) Yes 183 (6.57) 42 (3.70) 141 (8.43) Unknown 74 (3.31) 28 (3.06) 46 (3.47)	Yes	1585 (82.84)	501 (78.01)	1084 (85.97)	
No 1558 (82.07) 540 (86.28) 1018 (79.34) Yes 339 (17.24) 91 (13.43) 248 (19.70) Unknown 17 (0.70) 2 (0.30) 15 (0.95) CKD, n (%)	CVD, n (%)		· · · · ·		0.004
Yes 339 (17.24) 91 (13.43) 248 (19.70) Unknown 17 (0.70) 2 (0.30) 15 (0.95) CKD, n (%) 0.348 No 1614 (85.42) 544 (87.23) 1070 (84.25) Yes 205 (10.23) 53 (8.70) 152 (11.22) Unknown 95 (4.35) 36 (4.07) 59 (4.53) Hepatitis, n (%) 0.003 No 1657 (90.12) 563 (93.24) 1094 (88.11) Yes 183 (6.57) 42 (3.70) 141 (8.43) Unknown 74 (3.31) 28 (3.06) 46 (3.47)	No	1558 (82.07)	540 (86.28)	1018 (79.34)	
Unknown 17 (0.70) 2 (0.30) 15 (0.95) CKD, n (%) 0.348 No 1614 (85.42) 544 (87.23) 1070 (84.25) Yes 205 (10.23) 53 (8.70) 152 (11.22) Unknown 95 (4.35) 36 (4.07) 59 (4.53) Hepatitis, n (%) 0.003 No 1657 (90.12) 563 (93.24) 1094 (88.11) Yes 183 (6.57) 42 (3.70) 141 (8.43) Unknown 74 (3.31) 28 (3.06) 46 (3.47)	Yes	339 (17.24)	91 (13.43)	248 (19.70)	
CKD, n (%) 0.348 No 1614 (85.42) 544 (87.23) 1070 (84.25) Yes 205 (10.23) 53 (8.70) 152 (11.22) Unknown 95 (4.35) 36 (4.07) 59 (4.53) Hepatitis, n (%) 0.003 No 1657 (90.12) 563 (93.24) 1094 (88.11) Yes 183 (6.57) 42 (3.70) 141 (8.43) Unknown 74 (3.31) 28 (3.06) 46 (3.47)	Unknown	17 (0.70)	2 (0.30)	15 (0.95)	
No 1614 (85.42) 544 (87.23) 1070 (84.25) Yes 205 (10.23) 53 (8.70) 152 (11.22) Unknown 95 (4.35) 36 (4.07) 59 (4.53) Hepatitis, n (%) 0.003 No 1657 (90.12) 563 (93.24) 1094 (88.11) Yes 183 (6.57) 42 (3.70) 141 (8.43) Unknown 74 (3.31) 28 (3.06) 46 (3.47)	CKD, n (%)	、		· · · ·	0.348
Yes 205 (10.23) 53 (8.70) 152 (11.22) Unknown 95 (4.35) 36 (4.07) 59 (4.53) Hepatitis, n (%) 0.003 No 1657 (90.12) 563 (93.24) 1094 (88.11) Yes 183 (6.57) 42 (3.70) 141 (8.43) Unknown 74 (3.31) 28 (3.06) 46 (3.47)	No	1614 (85.42)	544 (87.23)	1070 (84.25)	
Unknown 95 (4.35) 36 (4.07) 59 (4.53) Hepatitis, n (%) 0.003 No 1657 (90.12) 563 (93.24) 1094 (88.11) Yes 183 (6.57) 42 (3.70) 141 (8.43) Unknown 74 (3.31) 28 (3.06) 46 (3.47)	Yes	205 (10.23)	53 (8.70)	152 (11.22)	
Hepatitis, n (%) 0.003 No 1657 (90.12) 563 (93.24) 1094 (88.11) Yes 183 (6.57) 42 (3.70) 141 (8.43) Unknown 74 (3.31) 28 (3.06) 46 (3.47)	Unknown	95 (4.35)	36 (4.07)	59 (4.53)	
No1657 (90.12)563 (93.24)1094 (88.11)Yes183 (6.57)42 (3.70)141 (8.43)Unknown74 (3.31)28 (3.06)46 (3.47)	Hepatitis, n (%)	(()	()	0.003
Yes 183 (6.57) 42 (3.70) 141 (8.43) Unknown 74 (3.31) 28 (3.06) 46 (3.47)	No	1657 (90.12)	563 (93.24)	1094 (88.11)	
Unknown 74 (3.31) 28 (3.06) 46 (3.47)	Yes	183 (6.57)	42 (3.70)	141 (8.43)	
	Unknown	74 (3.31)	28 (3.06)	46 (3.47)	

Table 1 (continued)				
Variables	Total (n = 1914)	Non-periodontitis/ mild periodontitis (n = 633)	Moderate/severe periodontitis (n = 1281)	Ρ
Dyslipidemia, n (%)				0.451
No	267 (11.30)	99 (11.58)	168 (11.11)	
Yes	1609 (87.44)	523 (87.59)	1086 (87.35)	
Unknown	38 (1.26)	11 (0.83)	27 (1.54)	
Autoimmune disease, n (%)				0.448
No	1713 (90.78)	564 (89.98)	1149 (91.30)	
Yes	201 (9.22)	69 (10.02)	132 (8.70)	
Decayed teeth, n (%)				<0.001
Yes	677 (30.67)	157 (21.03)	520 (36.91)	
No	10 (0.48)	1 (0.18)	9 (0.67)	
Unknown	1227 (68.85)	475 (78.79)	752 (62.42)	
Dental implant, n (%)				0.002
Yes	43 (2.33)	24 (3.92)	19 (1.30)	
No	1871 (97.67)	609 (96.09)	1262 (98.70)	
Tooth loss, n (%)				<0.001
1	311 (20.92)	192 (35.40)	119 (11.55)	
1—5	758 (42.67)	248 (41.33)	510 (43.54)	
≥6	845 (36.41)	193 (23.27)	652 (44.91)	
Dental floss use, times per week, Mean (S.E)	3.23 (0.09)	3.53 (0.12)	3.04 (0.15)	0.030
Total energy intake, kcal, Mean (S.E)	2014.56 (25.09)	2009.87 (45.26)	2017.60 (36.38)	0.904
Protein, gm, Mean (S.E)	81.25 (1.13)	80.25 (2.10)	81.90 (1.37)	0.529
Fiber, gm, Mean (S.E)	17.37 (0.35)	17.05 (0.59)	17.58 (0.39)	0.427
Ca, mg, Mean (S.E)	1118.11 (25.42)	1147.15 (33.55)	1099.34 (32.47)	0.274
Iron, gm, Mean (S.E)	19.26 (0.62)	19.82 (1.12)	18.91 (0.62)	0.450
Cu, mg, Mean (S.E)	1.59 (0.04)	1.59 (0.06)	1.60 (0.04)	0.866
Zn, mg, n (%)				0.003
\geq 11 (male) or \geq 8 (female)	748 (35.11)	212 (29.83)	536 (38.53)	
<11 (male) or $<$ 8 (female)	1166 (64.89)	421 (70.17%)	745 (61.47)	

DM: diabetes mellitus, SE: standard error, PIR: poverty income ratio, MET: metabolic equivalent, BMI: body mass index, WBC: white blood cell, CVD: cardiovascular disease, CKD: chronic kidney diseases, Ca: calcium, Cu: copper, Zn: zinc.

In subgroup analyses, we found in DM patients who aged >65 years old or were female, sufficient dietary Zn consumption was also related to low odds of periodontitis. Periodontitis is highly prevalent among American adults \geq 65 years of age,³⁰ and epidemiological studies and clinical observations have reported that the prevalence and severity of periodontitis increased with age.^{31,32} Loss of inflammation control in aging would aggravate the severity of periodontitis and was accompanied by the loss of balance between microorganisms and antibody.³³ The mechanism by which high levels of Zn intake may reduce the risk of periodontitis in older DM patients has not yet been elucidated, our results indicated that as an antioxidant metal element, adequate intake of Zn may mitigate its physiological loss in the elderly patients to achieve more significant anti-inflammatory and antioxidant effects in periodontitis.³⁴ We found the negative association between Zn intake and periodontitis also in female DM patients. Zorina et al.³⁵ considered that female was subjected to have a higher risk of chronic periodontitis with the Porphyromonas gingivalis (P. gingivalis) as the prevalent causative agent. In this study, there were respectively

58.65% male and 41.36% female DM patients in moderate/ severe periodontitis group, which indicating the gender distribution of the population is more balanced. There are also significant gender differences in DM. Biological risk factors for female include BMI, metabolic syndrome, sex hormones, and gestational diabetes mellitus (GDM).^{36,37} For female with DM, a lower intake of added sugar³⁸ and a higher intake of dietary fiber³⁹ appear to be important for reducing BMI and inhibiting *P. gingivalis*, while Zn-rich foods⁵ such as protein-rich foods and nuts can also lower cholesterol, and may play a role in reducing the risk of periodontitis.

This study explored the role of dietary Zn consumption in periodontitis, which may provide some references for lifestyle intervention for the prevention and control of periodontitis in DM patients. This large sample study was based on the NHANES database that used multi-stage complex sampling for better representation. In addition, periodontal testing was more comprehensive (covering 28 teeth, 6 positions per tooth). However, there are some limitations. This was a cross-sectional study that was unable to clarify the causal association between Zn intake and

Variables	OR (95% CI)	Р
Age	1.04 (1.03-1.05)	<0.001
Gender		
Male	Ref	
Female	0.54 (0.41–0.71)	<0.001
Race	P (
Mexican American	Ref	0.047
Other Hispanic	0.53 (0.31 - 0.89)	0.01/
Non-Hispanic White	0.43 (0.30 - 0.61)	<0.001
Non-Hispanic Black	0.64 (0.43-0.96)	0.030
Uther Race	0.68 (0.39–1.19)	0.169
Loss than 9th grade	Pof	
0 11th grade		0.001
High school graduate	0.40(0.23-0.72) 0.33(0.22-0.51)	<0.001
	0.33(0.22-0.31) 0.31(0.20-0.47)	<0.001
College graduate	$0.31(0.20 \ 0.47)$ 0.22 (0.14-0.34)	<0.001
Unknown	1 23 (0 10-14 38)	0.868
PIR	0.79 (0.72–0.86)	<0.000
Smoking	0.77 (0.72 0.00)	20.001
Never smoked	Ref	
Ouitting	1.44 (1.10-1.89)	0.008
Current smoker	2.69 (1.73-4.18)	< 0.001
Drinking		
No	Ref	
Yes	0.74 (0.54-1.01)	0.061
Physical activity	1.00 (1.00-1.00)	0.785
BMI	0.98 (0.96-1.00)	0.054
<25		
25–29.9	0.69 (0.40-1.19)	0.178
\geq 30	0.57 (0.35–0.91)	0.020
Diabetic retinopathy		
No	Ref	
Yes	1.14 (0.72–1.78)	0.574
Unknown	0.89 (0.64–1.25)	0.501
WBC	1.02 (0.95–1.10)	0.563
Antibiotics drug	P (
No	Ref	0 (()
Yes	1.06 (0.81–1.39)	0.643
Anti-diabetic drug	Def	
NO		0 4 2 9
Hypertension	0.77 (0.25–2.55)	0.030
No	Pof	
Ves	1 73 (1 31_2 27)	~0.001
CVD	1.75 (1.51 2.27)	<0.001
No	Ref	
Yes	1.60 (1.19-7.13)	0.002
Unknown	3.49 (0.50-24.22)	0.201
CKD		
No	Ref	
Yes	1.33 (0.86-2.08)	0.195
Unknown	1.15 (0.66-2.02)	0.609
Hepatitis		
No	Ref	
Yes	2.41 (1.50-3.88)	<0.001
Unknown	1.20 (0.59-2.45)	0.610
Dyslipidemia	,	

Table	2	Confounding	factors	related	to	the	periodon	titis
in the	curr	ent study.						

Variables	OR (95% CI)	Р
No	Ref	
Yes	1.04 (0.74-1.46)	0.820
Unknown	1.93 (0.65-5.76)	0.231
Autoimmune		
No	Ref	
Yes	0.86 (0.57-1.30)	0.454
Decayed teeth		
Yes	Ref	
No	2.09 (0.24-18.01)	0.496
Unknown	0.45 (0.33-0.61)	<0.001
Dental implant		
No		
Yes	3.09 (1.42-6.68)	0.005
Tooth loss		
1	Ref	
1—5	3.23 (2.24-4.65)	<0.001
>6	5.92 (4.10-8.54)	<0.001
Dental floss use	0.95 (0.90-0.99)	0.033
Total energy intake	1.00 (1.00-1.00)	0.905
Protein	1.00 (1.00-1.00)	0.533
Fiber	1.01 (0.99-1.02)	0.435
Ca	1.00 (1.00-1.00)	0.279
Iron	1.00 (0.99-1.00)	0.439
Cu	1.01 (0.90-1.13)	0.867

OR: odds ratio, CI: confidence interval, Ref: reference, PIR: poverty income ratio, BMI: body mass index, WBC: white blood cell, CVD: cardiovascular disease, CKD: chronic kidney diseases, Ca: calcium, Cu: copper.

periodontitis. The dietary intake of Zn was collected using the 24-h dietary recall that unable to avoid the influence of recall bias. And information related to plaque status and gingival treatment was not collected in the database, so the impact of these factors could not be assessed in this analysis.

Dietary Zn intake at the recommended level of intake may improve the onset and progression of periodontitis in patients with DM. Older patients as well as female patients

 Table 3
 Association
 between
 dietary
 7n
 intake
 and

periodontitis.			,	
Variables	Crude model		Adjusted model	
	OR (95% CI)	Р	OR (95% CI)	Р
Zn intake Not reach the recommended	Ref		Ref	
Reach the recommended level	0.68 (0.52–0.89)	0.006	0.76 (0.58–0.99)	0.044

Zn: zinc, OR: odds ratio, CI: confidence interval, Ref: reference. Adjusted model: adjusted for age, gender, race, PIR, smoking, and dental implants.

Subgroups	Crude mode	Adjusted mod	Adjusted model	
	OR (95% CI)	Р	OR (95% CI)	Р
Age <65 (n = 1216)				
Not reach the recommended level	Ref		Ref	
Reach the recommended level	0.70 (0.50-0.99)	0.046	0.82 (0.58-1.17)	0.268
Age \geq 65 (n = 698)				
Not reach the recommended level	Ref		Ref	
Reach the recommended level	0.61 (0.39-0.96)	0.032	0.59 (0.36-0.97)	0.038
Male (n = 996)				
Not reach the recommended level	Ref		Ref	
Reach the recommended level	0.67 (0.41-1.07)	0.092	0.75 (0.46-1.23)	0.253
Female (n = 918)				
Not reach the recommended level	Ref		Ref	
Reach the recommended level	0.64 (0.44-0.92)	0.016	0.71 (0.51-0.99)	0.048

Zn: zinc, OR: odds ratio, CI: confidence interval, Ref: reference.

Age subgroups: adjusted for gender, race, PIR, smoking, and dental implants.

Gender subgroups: adjusted for age, race, PIR, smoking, and dental implants.

should especially take care of the monitoring of oral conditions to prevent periodontitis.

Declaration of competing interest

The authors have no conflicts of interest relevant to this article.

Acknowledgments

None.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jds.2023.07.025.

References

- Hirtz C, O'Flynn R, Voisin PM, et al. The potential impact of salivary peptides in periodontitis. *Crit Rev Clin Lab Sci* 2021;58: 479–92.
- 2. Chen MX, Zhong YJ, Dong QQ, Wong HM, Wen YF. Global, regional, and national burden of severe periodontitis, 1990–2019: an analysis of the Global Burden of Disease Study 2019. *J Clin Periodontol* 2021;48:1165–88.
- 3. Preshaw PM, Alba AL, Herrera D, et al. Periodontitis and diabetes: a two-way relationship. *Diabetologia* 2012;55:21–31.
- 4. Sanz M, Ceriello A, Buysschaert M, et al. Scientific evidence on the links between periodontal diseases and diabetes: consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International diabetes Federation and the European Federation of Periodontology. *Diabetes Res Clin Pract* 2018;137:231–41.
- Dommisch H, Kuzmanova D, Jonsson D, Grant M, Chapple I. Effect of micronutrient malnutrition on periodontal disease and periodontal therapy. *Periodontology* 2018;78:129–53.

- Li W, Shang Q, Yang D, et al. Abnormal micronutrient intake is associated with the risk of periodontitis: a dose-response association study based on NHANES 2009-2014. *Nutrients* 2022; 14:2466.
- Gaur S, Agnihotri R. Trace mineral micronutrients and chronic periodontitis-a review. *Biol Trace Elem Res* 2017;176:225–38.
- Martins M, Oliveira A, Martins M, et al. Effects of zinc supplementation on glycemic control and oxidative stress in experimental diabetes: a systematic review. *Clin Nutr ESPEN* 2022; 51:28–36.
- **9.** Thomas B, Kumari S, Ramitha K, Ashwini Kumari MB. Comparative evaluation of micronutrient status in the serum of diabetes mellitus patients and healthy individuals with periodontitis. *J Indian Soc Periodontol* 2010;14:46–9.
- **10.** Tan J, Liu N, Sun P, Tang Y, Qin W. A Proinflammatory diet may increase mortality Risk in patients with diabetes mellitus. *Nutrients* 2022;14:2011.
- 11. Dye BA, Li X, Lewis BG, Iafolla T, Beltran-Aguilar ED, Eke PI. Overview and quality assurance for the oral health component of the national health and nutrition examination survey (NHANES), 2009-2010. J Publ Health Dent 2014;74:248–56.
- **12.** Dye BA, Afful J, Thornton-Evans G, Iafolla T. Overview and quality assurance for the oral health component of the national health and nutrition examination survey (NHANES), 2011-2014. *BMC Oral Health* 2019;19:95.
- **13.** Holtfreter B, Albandar JM, Dietrich T, et al. Standards for reporting chronic periodontitis prevalence and severity in epidemiologic studies: proposed standards from the Joint EU/USA Periodontal Epidemiology Working Group. *J Clin Periodontol* 2015;42:407–12.
- 14. Flack JM, Adekola B. Blood pressure and the new ACC/AHA hypertension guidelines. *Trends Cardiovasc Med* 2020;30: 160-4.
- **15.** Jellinger PS, Smith DA, Mehta AE, et al. American association of clinical endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. *Endocr Pract* 2012;18(Suppl 1):1–78.
- **16.** Niezen S, Trivedi HD, Mukamal KJ, Jiang ZG. Associations between alcohol consumption and hepatic steatosis in the USA. *Liver Int* 2021;41:2020–3.
- 17. Jespersen T, Kruse N, Mehta T, Kuwabara M, Noureddine L, Jalal D. Light wine consumption is associated with a lower odd

for cardiovascular disease in chronic kidney disease. *Nutr Metabol Cardiovasc Dis* 2018;28:1133–9.

- Martinon P, Fraticelli L, Giboreau A, Dussart C, Bourgeois D, Carrouel F. Nutrition as a key modifiable factor for periodontitis and main chronic diseases. J Clin Med 2021;10:197.
- Liu Y, Li X, Liu S, et al. The changes and potential effects of zinc homeostasis in periodontitis microenvironment. *Oral Dis* 2022. Epub ahead of print. PMID: 35996971.
- 20. Aziz J, Rahman MT, Vaithilingam RD. Dysregulation of metallothionein and zinc aggravates periodontal diseases. *J Trace Elem Med Biol* 2021;66:126754.
- Zhou F, Yao S, Shan F, Zhou Y. Serum zinc and periodontitis in non-diabetic smoking and non-smoking adults: NHANES 2011-2014. Oral Dis 2023. Epub ahead of print. PMID: 37338088.
- Najeeb S, Zafar MS, Khurshid Z, Zohaib S, Almas K. The role of nutrition in periodontal health: an update. *Nutrients* 2016;8: 530.
- 23. Olza J, Aranceta-Bartrina J, Gonzalez-Gross M, et al. Reported dietary intake and food sources of zinc, selenium, and vitamins A, E and C in the Spanish population: findings from the ANIBES Study. *Nutrients* 2017;9:697.
- 24. Rostan EF, DeBuys HV, Madey DL, Pinnell SR. Evidence supporting zinc as an important antioxidant for skin. *Int J Dermatol* 2002;41:606–11.
- Polenik P. Zinc in etiology of periodontal disease. Med Hypotheses 1993;40:182–5.
- 26. Lalla E, Lamster IB, Stern DM, Schmidt AM. Receptor for advanced glycation end products, inflammation, and accelerated periodontal disease in diabetes: mechanisms and insights into therapeutic modalities. Ann Periodontol 2001;6:113–8.
- 27. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. *Circ Res* 2010;106:842–53.
- Santana RB, Xu L, Chase HB, Amar S, Graves DT, Trackman PC. A role for advanced glycation end products in diminished bone healing in type 1 diabetes. *Diabetes* 2003;52:1502–10.

- 29. Lalla E, Lamster IB, Drury S, Fu C, Schmidt AM. Hyperglycemia, glycoxidation and receptor for advanced glycation endproducts: potential mechanisms underlying diabetic complications, including diabetes-associated periodontitis. *Periodontol* 2000 2000;23:50–62.
- Eke PI, Wei L, Borgnakke WS, et al. Periodontitis prevalence in adults >/= 65 years of age, in the USA. *Periodontology* 2016; 72:76-95.
- **31.** Eke PI, Dye BA, Wei L, et al. Update on prevalence of periodontitis in adults in the United States: NHANES 2009 to 2012. *J Periodontol* 2015;86:611–22.
- Eke PI, Dye BA, Wei L, et al. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res 2012;91: 914-20.
- Ebersole JL, Al-Sabbagh M, Gonzalez OA, Dawson 3rd DR. Ageing effects on humoral immune responses in chronic periodontitis. J Clin Periodontol 2018;45:680–92.
- Mocchegiani E, Malavolta M, Costarelli L, et al. Zinc, metallothioneins and immunosenescence. *Proc Nutr Soc* 2010;69: 290-9.
- Zorina OA, Aymadinova NK, Basovsmall aCcACAC, Shibaeva AV, Rebrikov DV. [Gender-related marker pathogens of periodontal disease in chronic periodontitis]. *Stomatologiia* 2016;95:10–6.
- **36.** Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. *Endocr Rev* 2016;37:278–316.
- Krejci CB, Bissada NF. Women's health issues and their relationship to periodontitis. J Am Dent Assoc 2002;133:323–9.
- Lula EC, Ribeiro CC, Hugo FN, Alves CM, Silva AA. Added sugars and periodontal disease in young adults: an analysis of NHANES III data. Am J Clin Nutr 2014;100:1182–7.
- Kim S, Park MH, Song YR, Na HS, Chung J. Aggregatibacter actinomycetemcomitans-induced AIM2 inflammasome activation is suppressed by xylitol in differentiated THP-1 macrophages. J Periodontol 2016;87:e116–26.